Profile data is unavailable for this security.
About the company
Merit Medical Systems, Inc. designs, develops, manufactures, markets and sells medical products for interventional and diagnostic procedures. The Company is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions and original equipment manufacturer. Within these product categories, it sells a variety of products, including cardiology and radiology devices, as well as embolotherapeutic, cardiac rhythm management, electrophysiology, critical care and others. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors.
- Revenue in USD (TTM)1.28bn
- Net income in USD101.95m
- Incorporated1987
- Employees6.95k
- LocationMerit Medical Systems Inc1600 West Merit Park WaySOUTH JORDAN 84095United StatesUSA
- Phone+1 (801) 253-1600
- Fax+1 (801) 253-1652
- Websitehttps://www.merit.com/
More ▼
Mergers & acquisitions
| Acquired company | MMSI:NSQ since announced | Transaction value |
|---|---|---|
| AngioDynamics Inc-Dialysis Catherer Portfolio & BioSentry Product | -4.04% | 100.00m |
| Bluegrass Vascular Technologies Inc-Surfacer Inside-Out Access Catheter System | -4.04% | 32.50m |
Data delayed at least 15 minutes, as of May 24 2024 20:56 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Envista Holdings Corp | 2.56bn | -120.40m | 3.09bn | 12.80k | -- | 0.7461 | 283.33 | 1.21 | -0.713 | -0.713 | 14.72 | 24.09 | 0.3904 | 3.89 | 6.29 | 200,226.60 | -1.83 | 1.94 | -2.15 | 2.34 | 56.35 | 57.65 | -4.70 | 5.29 | 1.93 | 5.09 | 0.2667 | 0.00 | -0.1012 | -2.04 | -142.10 | -- | -4.22 | -- |
| Tandem Diabetes Care Inc | 770.01m | -141.45m | 3.21bn | 2.40k | -- | 13.20 | -- | 4.17 | -2.17 | -2.17 | 11.82 | 3.76 | 0.8126 | 2.74 | 8.35 | 320,837.10 | -14.93 | -10.08 | -18.48 | -12.23 | 49.28 | 51.77 | -18.37 | -11.59 | 3.01 | -- | 0.5884 | -- | -6.68 | 32.39 | -135.33 | -- | 76.81 | -- |
| LivaNova PLC | 1.19bn | -31.77m | 3.22bn | 2.90k | -- | 2.63 | 191.07 | 2.71 | -0.5911 | -0.5911 | 21.89 | 22.56 | 0.4985 | 2.57 | 6.11 | 408,634.10 | -1.33 | -6.01 | -1.54 | -7.42 | 67.89 | 66.99 | -2.67 | -13.56 | 2.71 | 2.52 | 0.3383 | -- | 12.89 | 0.8278 | 120.34 | -- | -1.64 | -- |
| Procept Biorobotics Corp | 156.33m | -103.37m | 3.43bn | 626.00 | -- | 12.99 | -- | 21.95 | -2.12 | -2.12 | 3.20 | 5.14 | 0.4685 | 1.81 | 4.08 | 249,722.00 | -30.98 | -- | -34.68 | -- | 53.47 | -- | -66.12 | -- | 7.44 | -- | 0.1629 | -- | 81.55 | -- | -21.51 | -- | -- | -- |
| Axonics Inc | 387.14m | -15.95m | 3.44bn | 797.00 | -- | 5.48 | -- | 8.87 | -0.3134 | -0.3134 | 7.76 | 12.29 | 0.5606 | 1.20 | 8.53 | 485,744.00 | -2.31 | -12.67 | -2.52 | -13.76 | 75.25 | 70.04 | -4.12 | -29.68 | 8.04 | -- | 0.00 | -- | 33.86 | 249.06 | 89.80 | -- | 23.65 | -- |
| Integer Holdings Corp | 1.63bn | 98.09m | 4.08bn | 10.50k | 42.30 | 2.68 | 20.51 | 2.50 | 2.88 | 2.88 | 47.86 | 45.52 | 0.5452 | 4.91 | 4.95 | 155,494.60 | 3.28 | 3.28 | 3.53 | 3.53 | 26.54 | 26.94 | 6.01 | 6.40 | 2.01 | 3.74 | 0.4303 | 0.00 | 16.03 | 5.62 | 38.71 | 9.33 | 21.71 | -- |
| Haemonetics Corporation | 1.31bn | 117.56m | 4.50bn | 3.66k | 38.75 | 4.69 | 20.96 | 3.44 | 2.29 | 2.29 | 25.47 | 18.90 | 0.6339 | 2.10 | 6.79 | 357,958.70 | 5.69 | 5.02 | 6.57 | 6.07 | 53.69 | 51.74 | 8.98 | 8.11 | 1.50 | 18.09 | 0.457 | 0.00 | 12.01 | 6.23 | 1.87 | 16.40 | -11.04 | -- |
| TransMedics Group Inc | 296.92m | -10.20m | 4.53bn | 584.00 | -- | 28.33 | 4,136.86 | 15.26 | -0.335 | -0.335 | 8.96 | 4.85 | 0.5874 | 3.08 | 4.93 | 508,422.90 | -2.02 | -16.08 | -2.19 | -17.95 | 62.40 | 65.37 | -3.43 | -40.47 | 8.76 | -- | 0.7607 | -- | 158.53 | 79.36 | 30.92 | -- | 225.12 | -- |
| Inspire Medical Systems Inc | 660.91m | -15.73m | 4.60bn | 1.01k | -- | 7.80 | -- | 6.96 | -0.5374 | -0.5374 | 22.46 | 19.85 | 1.05 | 3.14 | 10.01 | 653,721.10 | -2.50 | -11.27 | -2.80 | -12.60 | 84.65 | 84.47 | -2.38 | -13.57 | 7.25 | -- | 0.00 | -- | 53.19 | 65.32 | 52.87 | -- | 148.37 | -- |
| Merit Medical Systems Inc | 1.28bn | 101.95m | 4.70bn | 6.95k | 46.38 | 3.79 | 24.11 | 3.66 | 1.74 | 1.74 | 21.96 | 21.35 | 0.64 | 2.32 | 7.32 | 184,648.80 | 5.08 | 2.45 | 5.65 | 2.77 | 46.54 | 44.50 | 7.94 | 3.91 | 4.38 | 11.61 | 0.3922 | 0.00 | 9.24 | 7.33 | 26.70 | 15.86 | -11.16 | -- |
| Glaukos Corp | 326.43m | -140.87m | 5.41bn | 907.00 | -- | 11.88 | -- | 16.58 | -2.88 | -2.88 | 6.68 | 9.04 | 0.3426 | 1.72 | 7.74 | 359,905.20 | -14.78 | -8.73 | -15.91 | -9.35 | 76.18 | 74.77 | -43.16 | -28.69 | 4.68 | -38.38 | 0.4395 | -- | 11.26 | 11.66 | -35.75 | -- | 14.44 | -- |
| Lantheus Holdings Inc | 1.37bn | 460.53m | 5.48bn | 834.00 | 12.06 | 5.79 | 10.50 | 4.01 | 6.55 | 6.55 | 19.42 | 13.64 | 0.8587 | 8.78 | 4.71 | 1,637,434.00 | 28.96 | 6.69 | 34.54 | 7.73 | 64.02 | 53.90 | 33.72 | 9.02 | 4.55 | -- | 0.3733 | 0.00 | 38.65 | 30.44 | 1,063.86 | 51.81 | 35.48 | -- |
| DENTSPLY SIRONA Inc | 3.94bn | -95.00m | 5.71bn | 15.00k | -- | 1.75 | 22.58 | 1.45 | -0.4468 | -0.4468 | 18.69 | 15.69 | 0.5326 | 2.94 | 6.02 | 262,666.70 | -1.24 | -1.14 | -1.52 | -1.32 | 52.61 | 53.65 | -2.34 | -2.51 | 0.9692 | 3.29 | 0.3908 | -- | 1.10 | -0.1071 | 86.11 | -- | -4.54 | 9.86 |
| Novanta Inc | 893.45m | 69.29m | 5.83bn | 2.90k | 84.49 | 8.55 | 49.77 | 6.52 | 1.92 | 1.92 | 24.77 | 18.99 | 0.6778 | 2.99 | 6.11 | 308,086.90 | 5.26 | 5.46 | 5.92 | 6.34 | 45.07 | 43.24 | 7.76 | 7.71 | 1.77 | 4.42 | 0.4319 | 0.00 | 2.41 | 7.49 | -1.58 | 8.21 | 4.19 | -- |
| Stevanato Group SpA | 1.17bn | 147.24m | 6.08bn | 5.64k | 36.29 | -- | 31.69 | 5.19 | 0.5553 | 0.5553 | 4.41 | -- | -- | -- | -- | 207,886.90 | -- | -- | -- | -- | 30.81 | -- | 12.57 | -- | -- | 32.91 | -- | -- | 10.34 | -- | 1.95 | -- | -- | -- |
Data as of May 24 2024. Currency figures normalised to Merit Medical Systems Inc's reporting currency: US Dollar USD
51.98%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 8.47m | 14.62% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 6.66m | 11.49% |
| William Blair Investment Management LLCas of 31 Mar 2024 | 3.07m | 5.29% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.24m | 3.87% |
| ArrowMark Colorado Holdings LLCas of 31 Mar 2024 | 2.19m | 3.77% |
| Conestoga Capital Advisors LLCas of 31 Mar 2024 | 2.17m | 3.75% |
| Fuller & Thaler Asset Management, Inc.as of 31 Mar 2024 | 1.46m | 2.52% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 1.32m | 2.28% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.29m | 2.23% |
| Macquarie Investment Management Business Trustas of 31 Mar 2024 | 1.25m | 2.15% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
